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Reproducibility of Fuhrman Nuclear Grading of Renal
Cell Carcinoma: A Preliminary Study*
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Background: The aim of this study was to evaluate intraobserver and interobserver reproducibility of
Fuhrman nuclear grading of renal cell carcinoma.
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Methods: Pathology slides from 46 cases of renal cell carcinoma were rescored by 2 pathologists according
to the Fuhrman system. Both intraobserver and interobserver reproducibility were assessed using kappa
statistics.
Results: The initial Fuhrman grade was grade 1 in 4 of the cases (8.7%), grade 2 in 30 (65.2%), grade 3 in
11 (23.9%), and grade 4 in 1 (2.2%). After reviewing the slides by the same pathologist, grades were
reassigned as follows: grade 1 in 8 cases (17.4%), grade 2 in 23 (50%), grade 3 in 14 (30.4%), and grade
4 in 1 (2.2%). Intraobserver reproducibility of the Fuhrman system was substantial (κ = 0.66). Fuhrman
grading by the second pathologist was grade 1 in 11 cases (23.9%), grade 2 in 27 (58.7%), grade 3 in 7
(15.2%), and grade 4 in 1 (2.2%). Interobserver reproducibility of the Fuhrman system was moderate (κ =
0.42).
Conclusions: Despite substantial intraobserver reproducibility of Fuhrman grading, moderate interobserver
reproducibility and low agreement for grade 3 should be a consideration.
Key Words: Fuhrman nuclear grade, renal cell carcinoma, reproducibility
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Renal Hücreli Karsinomda Fuhrman Nükleer
Derecenin Tekrarlanabilirliği: Ön Çalışma
Amaç: Bu çalışmada, renal hücreli karsinomda Fuhrman nükleer derece sisteminin gözlemci içi ve gözlemciler
arasındaki tekrarlanabilirliğini değerlendirmek amaçlanmıştır.
Metot: 46 renal hücreli karsinom olgusuna ait histolojik kesitler, iki patolog tarafından Fuhrman sistemine
göre yeniden skorlanmıştır. Patologlar arasında gözlemci içi ve gözlemciler arasındaki tekrarlanabilirlik kappa
istatistiği ile değerlendirilmiştir.
Bulgular: Birinci patoloğun ilk değerlendirmesinde; derece 1: dört (% 8,7), derece 2: otuz (% 65,2), derece
3: on bir (% 23,9) ve derece 4: bir (% 2,2) olguda belirlenmiştir. Aynı patoloğun ikinci değerlendirmesinde;
derece 1: sekiz (% 17,4), derece 2: yirmi üç (% 50), derece 3: on dört (% 30,4) ve derece 4: bir (% 2,2)
olguda saptanmıştır. Fuhrman sisteminin gözlemci içi tekrarlanabilirliği güçlü düzeyde bulunmuştur (κ =
0,66). İkinci patoloğun Fuhrman derecelendirmesinde; derece 1: on bir (% 23,9), derece 2: yirmi yedi (%
58,7), derece 3: yedi (% 15,2) ve derece 4: bir (% 2,2) olguda belirlenmiştir. Fuhrman sisteminin gözlemciler
arasındaki tekrarlanabilirliği ise orta düzeyde bulunmuştur (κ = 0,42).
Sonuç: Fuhrman derecenin gözlemci içi güçlü tekrarlanabilirliğine rağmen, gözlemciler arasında orta
düzeydeki tekrarlanabilirliği ve derece 3’teki düşük uyum göz önünde tutulmalıdır.
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Renal cell carcinoma (RCC) accounts for 90% of all primary malignant renal tumors
in adults of both sexes (1-3). Staging and nuclear grading of RCC are considered
important predictors of survival (1-5). Numerous grading systems have been developed
for RCC. Skinner et al. (6) were the first to propose a grading system based solely on
nuclear morphology, in 1971, which was later simplified by Fuhrman et al. in 1982 (7).
Currently, the Fuhrman system is the most widely used nuclear grading system for
* Presented at the 21st European Congress of Pathology, İstanbul, Turkey, 2007. Virchows Archive
Supplement 2007; 451: 406.
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grading RCC (4,8,9). The system is based on nuclear size,
shape, and prominence of nucleoli (7). Despite wide
acceptance of the Fuhrman nuclear grading system, its
reproducibility has been questioned. There is a limited
number of series that have assessed intraobserver and
interobserver variability of the Fuhrman system. The aim
of the present preliminary study was to assess
intraobserver and interobserver reproducibility among 2
pathologists of the Fuhrman nuclear grading system for
RCC.

between the original and reviewed nuclear grades (fair
agreement, κ = 0.00-0.20; moderate agreement, κ =
0.21-0.45; substantial agreement, κ = 0.46-0.75; nearperfect agreement, κ = 0.76-0.99; perfect agreement, κ
= 1.00). Slides of all the cases were pathologically staged
by the first pathologist according to the 1997 TNM
criteria. Tumor sizes were also recorded. The relationship
between Fuhrman nuclear grade and pathologic stage
were determined by correlation analysis with Pearson’s
correlation coefficients.

Materials and Methods

Results

This study included 46 patients that had undergone
radical nephrectomy for RCC at the pathology
departments of the Faculty of Medicine, Zonguldak
Karaelmas University and Lutfi Kirdar Kartal Training and
Research Hospital between 2005 and 2007. The
histopathological types of the 46 RCCs were conventional
(n = 37, 80.4%), chromophobe (n = 5, 10.9%), and
papillary (n = 4, 8.7%). Clinical features were obtained
from hospital records. All histopathological sections were
fixed in formalin, embedded in paraffin, cut into 5 μm
sections, and stained with hematoxylin and eosin (H&E).

Mean age of the patients was 59.37 ± 11.89 years
(range: 32-80 years). Sixteen patients (34.8%) were
female and 30 (65.2%) were male. Maximum tumor
diameter ranged from 2 to 14 cm (mean: 6.78 ± 3.14)
(Table 1).

Slides of all the cases were rescored according to the
Fuhrman nuclear grading system by 2 pathologists
blinded to the original scores. There was a 2-month
interval between each grading round. Tumors were
graded as follows: grade 1 tumors were composed of
cells with small (~10 μm), round, uniform nuclei and
inconspicuous or absent nucleoli; grade 2 tumor cells had
larger (~15 μm) nuclei with irregular outlines and
nucleoli that were visible under high-power (400×)
microscopy; grade 3 tumor cells had even larger nuclei
(~20 μm) with obviously irregular outlines and
prominent nucleoli, even under low-power (100×)
microscopy; grade 4 tumors exhibited features similar to
grade 3 tumors, but also had bizarre and multilobed
nuclei, and clumped chromatin. The nuclear grade was
assigned to each tumor according to its least
differentiated area (7).
Intraobserver variation was determined as the first
pathologist’s grading at 2 different times. Interobserver
variation was determined by the second pathologist, who
did not know the first pathologist’s results. Data were
analyzed using SPSS v.11.0 (SPSS, Chicago, IL, USA).
Kappa statistics was used to evaluate the concordance
186

The initial Fuhrman nuclear grade was grade 1 in 4
patients (8.7%), grade 2 in 30 (65.2%), grade 3 in 11
(23.9%), and grade 4 in 1 (2.2%). The coexistence of 2
different grades in the same tumor was observed in
47.8% of the cases. After reviewing slides by the same
pathologist, nuclear grades were reassigned as follows:
grade 1 in 8 patients (17.4%), grade 2 in 23 (50%),
grade 3 in 14 (30.4%), and grade 4 in 1 (2.2%).
Intraobserver reproducibility of Fuhrman nuclear grading
was substantial (κ = 0.66); 37 (80.4%) of the cases were
given concordant grades by the first pathologist. Tumors
originally classified as grade 1 were upgraded by 1 grade
in 25% of the cases. Tumors originally classified as grade
2 were upgraded by 1 grade in 10% of the cases. Tumors
originally classified as grade 3 and grade 4 remained
unchanged (100%) (Table 2).
Fuhrman nuclear grading of the second pathologist
was grade 1 in 11 patients (23.9%), grade 2 in 23
(58.7%), grade 3 in 7 (15.2%), and grade 4 in 1
(2.2%). Interobserver reproducibility of Fuhrman nuclear
grading was moderate (κ = 0.42); the same grade was
obtained by the 2 pathologists in 31 of the cases
(67.4%). Tumors classified as grade 1 by the first
pathologist were upgraded by 1 grade in 25% of the
cases. Tumors classified as grade 2 by the first
pathologist were upgraded by 1 grade in 3.3% of the
cases. Tumors classified as grade 3 by the first
pathologist were under graded by 1 grade in 45.5% of
the cases. Tumors originally classified as grade 4
remained unchanged (100%) (Table 3).

Vol: 39

Reproducibility of the Fuhrman Nuclear Grading

No: 2

Table 1. Clinicopathological features of the 46 patients with RCC.

Clinicopathological Features

Number of Patients (%)

Age
Mean ± SD
Range

59.37 ± 11.89
32-80

Gender
Male
Female

30 (65.2)
16 (34.8)

Tumors were pathological stage 1 in 29 patients
(63%), stage 2 in 13 patients (23.3%), stage 3 in 2
patients (4.3%), and stage 4 in 2 patients (4.3%).
Pathologic stage was significantly correlated with initial (r
= 0.66, P = 0.01) and reviewed (r = 0.50, P = 0.01)
Fuhrman nuclear grades (r = 0.57, P = 0.01) (Figure).
4

Tumor size (cm)
Mean ± SD
Range

April 2009

Original FNG of the
first pathologist
Reviewed FNG of the
first pathologist

6.78 ± 3.14
2-14

FNG of the second
pathologist
37 (80.4)
5 (10.9)
4 (8.7)

Pathologic stage
1
2
3
4

29 (63)
13 (28.3)
2 (4.3)
2 (4.3)

3

Mean

Histopathological type
Conventional
Chromophobe
Papillary

2

SD: Standard deviation. Tumor size: Represents the single greatest
dimension.

Intraobserver agreement for Fuhrman nuclear
grading was 75% for grade 1, 73.3% for grade 2,
100% for grade 3, and 100% for grade 4. Interobserver
agreement for Fuhrman nuclear grading was 75% for
grade 1, 70% for grade 2, 54.5% for grade 3, and
100% for grade 4. The x test for homogeneity was
performed to determine if proportions of the
pathologists’ grades revealed a similar pattern. The null
hypothesis of similarity was rejected for both grading
rounds (P < 0.001).

1
1
2
Pathologic stage

3

4

FNG: Fuhrman nuclear grade
Figure.

Relationship between pathologic stage and Fuhrman nuclear
grade assigned by the 2 pathologists.

Table 2. Intraobserver reproducibility of Fuhrman nuclear grades.

Reviewed assessment
Fuhrman nuclear grade

1

2

3

4

Number of cases

1

3

1

-

-

4

Initial

2

5

22

3

-

30

assessment

3

-

-

11

-

11

4

-

-

-

1

1

Number of cases

8

23

14

1

46

κ = 0.66
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Table 3. Interobserver reproducibility of Fuhrman nuclear grades.
Second pathologist

First
pathologist
(initial
assessment)

Fuhrman nuclear
grade

1

2

3

4

Number of cases

1
2
3
4
Number of cases

3
8
11

1
21
5
27

1
6
7

1
1

4
30
11
1
46

κ = 0.42

Discussion
The Fuhrman nuclear grading system is currently the
most widely used grading system for RCC worldwide
(4,7,8). It is applicable to any size, pattern, and cell-type
of RCC (7). It has been shown that this nuclear grading
system has prognostic value, especially for conventional
and papillary RCCs (9). The Fuhrman grading system is
widely accepted because of its simplicity and proven
correlation with other pathologic variables. In the present
study pathologic stage was significantly correlated with
the Fuhrman nuclear grades of both pathologists. Several
studies have reported differences in RCC-specific survival
after separating cases with grade 1-2 tumors from those
with grade 3-4 tumors. Additionally, the prognostic value
of the Fuhrman nuclear grading system has been
confirmed by most studies; patients with grade 3 or 4
tumors had less favorable prognoses than those with
grade 1 or 2 tumors (10-16). Problems with Fuhrman
nuclear grading include intraobserver and interobserver
variability and reproducibility among pathologists, and
this variability has been explored in several published
studies.
In the present study intraobserver agreement was
substantial (κ = 0.66, 80.4% concordance rate) and
higher than that reported by Al-Aynati et al. (κ = 0.29 to
0.62, mean: 0.45) (17); however, interobserver
agreement was moderate (κ = 0.42, 67.4% concordance
rate), which is consistent with the results obtained by
Ficarra et al. (κ = 0.44) (17), Lanigan et al. (κ = 0.33)
(18), Al-Aynati et al. (κ = 0.19 to 0.44, mean: 0.29)
(19), and Lang et al. (κ = 0.09 to 0.36, mean; 0.22)
(20). The interobserver concordance rate (67.4%)
obtained in the present study is lower than that reported
by Bretheau et al. (95%) (21). In the present study
intraobserver agreement for Fuhrman nuclear grades 3
188

(100%) and 4 (100%) was high, as was interobserver
agreement for grades 1 (75%) and 4 (100%); however,
intraobserver agreement for Fuhrman nuclear grade 2
(73.3%) and interobserver agreement for grade 3 were
lower (54.5%).
Intraobserver and interobserver variability for
Fuhrman nuclear grading can be due to several factors.
First, RCC is a heterogeneous tumor that is usually
composed of cells of different grades. In the presented
series coexistence of 2 grades in the same tumor was
observed in 47.8% of the cases. Fuhrman nuclear grade
depends on the outlines of cell nuclei, the presence of
nucleoli, and nuclear size, and must therefore be
determined according to the least differentiated cell
component (7). Searching for the least differentiated
component is a time consuming procedure and requires
investigating all tumor slides carefully, which may
contribute to the variability in grading among
pathologists. Sampling an inadequate number of tumors
and suboptimal tissue fixation may be other challenging
factors in the identification of the area with the highest
grade. A homogeneous appearance in grade 1 RCCs and
bizarre, multilobed nuclei in grade 4 tumors might
contribute to higher grading reproducibility. On the other
hand, pathologist subjectivity in assessing nuclear shape,
cell outlines, and the presence of nucleoli in grade 2 and
3 tumors might be the cause of lower reproducibility.
Several variants of the Fuhrman grading system have
recently been described (22). It has been suggested that
collapsing the Fuhrman grading system into a 2- or 3tiered scheme can improve intraobserver and
interobserver reproducibility (17). The use of nuclear
morphometry in conjunction with histopathological
grading may ensure more objective assessment of RCCs
(23,24).
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Fuhrman nuclear grading of RCC has shown a
significant prognostic correlation with metastatic
potential and patient survival in several studies (10-16);
however, studies measuring intraobserver and
interobserver agreement of Fuhrman grade show poor
results in terms of reproducibility. In the current study,

April 2009

intraobserver and interobserver agreement were
substantial and moderate, respectively. These variations
can be explained, to a certain degree, by pathologist
subjectivity in application of nuclear grades. There
remains a need for improved standardization of nuclear
criteria.
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